New study tracks how apalutamide works outside of clinical trials
NCT ID NCT06019676
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This observational study follows 170 men with metastatic hormone-sensitive prostate cancer who are taking apalutamide as part of their standard care. Researchers will measure PSA levels and use questionnaires to assess fatigue, thinking skills, and quality of life over two years. The goal is to see how well the drug works in everyday practice, beyond the strict conditions of earlier clinical trials.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
apalutamide
What this could lead to
If successful, this study could provide real-world evidence on how well apalutamide works and its side effects, helping doctors make better treatment decisions for men with metastatic prostate cancer.
What could go wrong
This is an observational study, not a controlled trial, so results may be less definitive. It only includes men already choosing apalutamide, which may limit how broadly findings apply.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC HORMONE-SENSITIVE PROSTATE CANCER (MHSPC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust
Cambridge, CB2 0QQ, United Kingdom
-
Buckinghamshire Healthcare NHS Trust
Aylesbury, HP21 8AL, United Kingdom
-
Clatterbrdige Cancer Centre, NHS Foundation Trust
Liverpool, CH63 4JY, United Kingdom
-
East Lancashire Hospitals NHS Trust
Blackburn, BB2 3HH, United Kingdom
-
Freeman Hospital, The Newcastle upon Tyne Hospitals NHS Foundation Trust
Newcastle, NE7 7DN, United Kingdom
-
Northern Ireland Cancer Centre, Belfast Health & Social Care Trust
Belfast, BT9 7AB, United Kingdom
-
South Tyneside and Sunderland NHS Foundation Trust
Newcastle, NE34 0PL, United Kingdom
-
The James Cook University Hospital, South Tees Hospitals NHS Foundation Trust
Middlesbrough, TS4 3BW, United Kingdom
-
The Royal Marsden Hospital
Sutton, Surrey, SM2 5PT, United Kingdom
-
The University Hospital of North Tees
Stockton-on-Tees, TS19 8PE, United Kingdom
-
University Hospitals of Morecambe Bay NHS Foundation Trust
Lancaster, LA1 4RP, United Kingdom
-
Velindre Cancer Centre, Velindre University NHS Trust
Cardiff, CF14 2TL, United Kingdom